Onera Health – a pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere – recently announced the completion of its Series C financing round. This latest funding round brings Onera’s total investment to over €55 million.
The funding round was led by new investor EQT Life Sciences, investing from its EQT Health Economics 3 fund, co-led by new investor Gimv, and joined by existing investors, including Innovation Industries, Invest-NL, imec.xpand, BOM, and 15th Rock.
This funding will enable the company to accelerate manufacturing and deployment plans to meet the growing customer demand for its innovative, self-applied, no-wire end-to-end solution. And the company plans to use the funds to expedite the clearance of the second generation of its polysomnography (PSG) system in Europe and the United States, further underlining the ambition to position itself as a leader in home PSG (hPSG) within the field of sleep medicine.
Onera Health focuses on breakthrough sleep testing solutions that are quick, convenient, and clinically accurate. And the user-centric technology of their PSG system brings clinical-grade PSG diagnostics and monitoring directly to the patient’s bed from the comfort of their own home. The MedTech and Digital Health company operates in the U.S., the Benelux, and the DACH region.
As part of this deal, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.
KEY QUOTES:
“We are delighted that two premier Life Sciences investors, as well as our existing world-class investors, have the confidence to join and support us in the next phase of our company journey. This capital infusion will accelerate our ability to scale in the US and Europe. We will continue aggressively investing in R&D, customer success, and geographic expansion to help the medical field provide the much-needed answers for millions of people affected by sleep disorders. We are incredibly proud and humbled by our success to date and look forward to driving growth together with our new partners.”
— Ruben de Francisco, Founder and CEO of Onera Health
“Onera Health, with its disruptive medical technology, is a perfect fit for the EQT Health Economics strategy. We are dedicated to growing companies with the potential to have a meaningful impact on society, and Onera is strongly aligned with this mission. The company demonstrated a very strong product-market fit with great potential to improve the quality of patient care while also positively impacting the cost of healthcare. We could not be more thrilled to be supporting the next phase of their journey.”
— Drew Burdon, Partner at EQT Life Sciences
“Gimv’s Life Sciences’ partnership with Onera Health is driven by the shared commitment to addressing unmet clinical needs. Onera is perfectly positioned to support the continued growth potential of hospital-quality care at the patient’s home through its innovative sleep diagnostic solution. With its top-notch team and innovative patch-based technology, we believe Onera can and will democratize the gold-standard in sleep medicine.”
— Michaël Vlemmix, Partner at Gimv Life Sciences
